هل السرطان مرض وراثي ؟

الكاتب : د. أم الخير

المراجع

World Health Organization (WHO): Cancer(2022) accessed: September 20,2025:http/www.who.int/health topic. 2025.

Zhou J, Zhou XA, Zhang N, Wang J: Evolving insights: how DNA repair pathways impact cancer evolution . Cancer Biol Med. 2020, 17:805-27. 10.20892/j.issn.2095-3941.2020.0177

Alqahtani WS,Almufareh NA,Domaity DMetal Epidemiology of Cancer in Saudi Arabia Thru 2010–2019: A Systematic Review with Constrained Meta-analysis AIMS Public Health,2020,7679-96.

NCR2022.

Knowledge of cancer genetics and the importance of genetic testing: A Public health study Curenes 8/6/2023.

Wang Q: Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes. Acta Pharmacol Sin. 2016, 37:143-9. 10.1038/aps.2015.89

Daly MB, Pilarski R, Axilbund JE, et al.: Genetic/familial high-risk assessment: breast and ovarian, version 2.2015. J Natl Compr Canc Netw. 2016, 14:153-62. 10.6004/jnccn.2016.0018

Hall, JM., Lee, MK., Newman, Betal. Linkage of early onset familial breast cancer to chromosome 17Q21. Science 1990; 250: 1684-1689.

Wooster R., Neuhausen, SL., Mangion, Jetal. Localization of a Breast Cancer Susceptibility Gene, BRCA2 to Chromosome 13q12-13. Science 1994; 265: 2088-2090.

Stratton MR., RahmanN. The Emerging Landscape of Breast Cancer Susceptibility NAT Gene 2008; 40: 17-22.

King, MC., MarkJH., MandellJB., New York Breast Cancer Study Group. Breast and ovarian cancer risk due inherited mutation in BRCA1 and BRCA2. Science 2003; 302: 643-646.

Lindor, NM، McMaster ML., Lindor, Cjet al. Concise Handbook of Familial Cancer Susceptibility Syndromes, Second edition. J Nat Cancer Inst Monogr 2008; 1-93.

LiedeA., Karlan BY., NARODSA. Cancer Risks for male carriers of germline .mutation in BRCA1 or BRCA2: A Review of the JCLIN Oncol 2004; 22: 735-742.

The Breast Cancer Linkage Consortium. Cancer risk in BRCA2 mutation carriers. J Nat Cancer Inst 1999; 91: 1310-1316.

ThompsonD1, Easton DF. Breast Cancer linkage C., Cancer incidence in BRCA1 mutation Carriers: J Nat Cancer Inst 2002; 94: 1358-1365.

Domchek SM., TangJ., StopferJetal. Biallelic deletereous BRCA1 mutations in women with early onset ovarian cancer. Cancer Discov 2013; 3: 399-405.

Rakha EA., Reis-FilhoJS., ElLiSIO. Basal Like Breast Cancer, A Critical Review. JCLin Oncol 2008; 26: 2568-2581.

LakhaniSR., Van De VijverMJ, Jacquemier, Jetal. The pathology of familial breast cancer: predictive value of immunohistochemical markers, estrogen receptors, progesterone receptors, HER2, and p53 in patients with mutations in BRCA1 and BRCA2. JClin Oncol 2002; 20: 2310-2318.

AntinioAC., Easton DF. Models of Genetic susceptibility to Breast Cancer. RES Treat 2012; 136: 931-933.

El-Harith HA, Abdel-Hadi MS, Steinmann D, et al: BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia. Saudi Med J 23:700-704, 2002

Alshatwi AA, Shaf G, Hasan TN, et al: Single nucleotide Polymorphisms in the P21 and BCL2 Cancer susceptibility Genes and Breast Cancer Risk in Saudi Arabia. Asian Pac J Cancer Prev 12:2607-2610, 2011.

Al-Moghrabi N, Al-Qasem AJ, Aboussekhra A: Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women. Int J Oncol 39:129-135, 2011.

Alanazi M, Pathan AA, Abduljaleel Z, et al: Association between PARP-1 V762A Polymorphism and breast Cancer susceptibility in Saudi Population. PLOS One 8:E85541, 2013.

Hasan TN, Shafi G, Syed NA, et al: Lack of association of BRCA1 and BRCA2 variants with breast cancer in an ethnic population of Saudi Arabia, an emerging high-risk area. Asian Pac J Cancer Prev 14:5671-5674, 2013.

Bu R, Siraj AK, Al-Obaisi KA, et al: Identification of Novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and sanger sequencing Analysis. Int J Cancer 139:1091-1097, 2016.

Prevalence of BRCA1 and BRCA2 mutations among high-risk Saudi patients with breast cancer. OmalKhair Abdullah, Mohammed AlBalwai ,RunBanu and Ezzeldin Ibrahim. JGO 2018 (Journal of Global Oncology).

Gene of Breast cancer: a topic in Evolution. S., Shiovitz aL.A, Karde. Annals Oncology 26: 1291-1299 2015.

لماذا يفشل العلاج الكيميائي أحيانًا؟ بصمات الجينات تكشف السر

الكاتب: د. عائشة النعمي

المراجع

Thompson, J. S., Madrid, L., Hernando, B., Sauer, C. M., Vias, M., Escobar-Rey, M., … & Macintyre, G. (2025). Predicting resistance to chemotherapy using chromosomal instability signatures. Nature Genetics, 1-10.‏